CGH
PCRX icon

Cleary Gull Holdings’s Pacira BioSciences PCRX Stock Holding History

Cleary Gull Holdings’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-207
Closed -$16K – 104
2015
Q4 		$16K Buy
+207
New +$11.7K 0.01% 59

Other funds holding PCRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Cleary Gull Holdings's PCRX Position: Q1 2016 in Review

Cleary Gull Holdings sold out of Pacira BioSciences (PCRX) in Q1 2016, closing a stake of 207 shares — an estimated $16K sold.

Cleary Gull Holdings first reported a position in PCRX in Q4 2015 and held it in 1 quarter. The position peaked at $16K in Q4 2015. 180 funds tracked by Wall St. Rank hold PCRX as of Q1 2016.

  • Cleary Gull Holdings reported no remaining Pacira BioSciences position as of Q1 2016 after selling out during the quarter.
  • Cleary Gull Holdings sold 207 Pacira BioSciences shares in Q1 2016, an estimated $16K.
  • Cleary Gull Holdings first reported a position in Pacira BioSciences in Q4 2015 and held it in 1 quarter.
  • Cleary Gull Holdings's Pacira BioSciences position peaked at $16K in Q4 2015.
  • 180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2016.

Based on Cleary Gull Holdings's 13F filing for Q1 2016, filed 9 May 2016.